MLAB
NASDAQ · Life Sciences Tools & Services
Mesa Laboratories Inc
$93.27
+2.07 (+2.27%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 245.59M | 224.59M | 390.77M | 397.89M | 376.18M |
| Net Income | -2,011,584 | -1,655,624 | 30.99M | 29.46M | 36.94M |
| EPS | — | — | — | — | — |
| Profit Margin | -0.8% | -0.8% | 7.9% | 7.4% | 9.8% |
| Rev Growth | +9.4% | +9.4% | -3.9% | +8.2% | -1.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 135.74M | 135.74M | 73.43M | 71.22M | 83.37M |
| Total Equity | 121.91M | 121.91M | 380.57M | 387.20M | 405.59M |
| D/E Ratio | 1.11 | 1.11 | 0.19 | 0.18 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 34.98M | 30.39M | 57.48M | 61.24M | 58.33M |
| Free Cash Flow | — | — | 25.92M | 38.36M | 33.12M |